Osprey Study Chosen for “Best of Best” Presentation at Society for Cardiovascular Angiography and Interventions Conference

MINNESOTA, United States--()--Osprey Medical (ASX:OSP) today announced a multi-center observational study for the DyeVert Plus™ System will feature at the Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Session in April 2018.

The abstract entitled: A Multi-Center Observational Study of the DyeVert Plus™ Contrast Reduction System summarizes a single-arm, multi-center observational study designed to evaluate DyeVert Plus™ use in patients undergoing common heart imaging procedures. The primary outcome for the study was percentage of dye volume saved with secondary outcomes of dye-related and device related adverse events.

Of the 370 abstracts accepted, the DyeVert Plus study was among 25 chosen as the “Best of Best,” which will include a featured display and moderated presentation during the scientific session on April 26th. One of these 25 will further be selected as Best Abstract of Show. Study results are sequestered until publication, which is expected on April 26, 2018.

SCAI Scientific Session is attended by more than 2,000 physicians, cardiovascular professionals, hospital administrators, academics, and industry professionals from around the world to share knowledge, clinical expertise, and the latest medical advances, with the single goal of advancing care to save and enhance lives.

DyeVert Plus™ is an FDA cleared device designed to reduce dye volume used during normal heart imaging procedures and permits real time monitoring of administered. It is the only FDA cleared product with the claim of reduced dye delivery to the patient without impacting image quality.

About Osprey

Osprey Medical is focused on protecting patients from the harmful effects of X-ray dye (contrast) used during commonly performed angiographic imaging procedures. The Company’s core technologies originated from research conducted by Dr David Kaye at Melbourne’s Baker IDI Heart and Diabetes Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage. The Company’s DyeVert™ Plus System is a next-generation product that reduces contrast while maintaining image quality in a self-adjusting easy-to-use design. Osprey Medical’s Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical’s advisory board comprises world-recognised experts in heart and kidney diseases.

Contacts

Media
Buchan Consulting
Amanda Loh, (613) 8866 1210
aloh@buchanwe.com.au
or
Company
Doug Schoenberg, 952-955-8230
VP of Marketing
dschoenberg@ospreymed.com

Recent Stories

RSS feed for Osprey Medical

Release Summary

Minnesota-based medical device company Osprey Medical announced a study for its DyeVert Plus will feature in a SCAI Scientific Session presentation

Osprey Medical